Acute pain

Mainstay Medical Announces Limited Commercial Launch of ReActiv8® in the U.S.

Retrieved on: 
Tuesday, June 29, 2021
General Health, Health, Medical devices, Branches of biology, Nervous system, Medicine, Neurotechnology, Pain, Acute pain, Electrotherapy, Neurostimulation, Implant, Low back pain, Neuromodulation, Mainstay Medical, ReActiv8®, Chronic Low Back Pain, MAINSTAY MEDICAL, REACTIV8®, CHRONIC LOW BACK PAIN

Mainstay Medical Holdings plc (the Company) today announced the limited commercial launch in the U.S. of ReActiv8, its implantable Restorative Neurostimulation system to treat intractable chronic low back pain.

Key Points: 
  • Mainstay Medical Holdings plc (the Company) today announced the limited commercial launch in the U.S. of ReActiv8, its implantable Restorative Neurostimulation system to treat intractable chronic low back pain.
  • Physicians will finally have access to a therapy to treat these patients beyond temporary treatments designed to merely mask the pain for a limited time, said Jason Hannon, CEO of Mainstay Medical.
  • To support the U.S. commercial launch, Mainstay Medical has launched a new corporate website centered around patient and physician education.
  • Mainstay Medical is a medical device company focused on commercializing an innovative implantable Restorative Neurostimulation system, ReActiv8, for people with disabling mechanical Chronic Low Back Pain (CLBP).

A Performance and Lifestyle Brand For Ambitious Individuals

Retrieved on: 
Friday, June 25, 2021
Acute pain, Nervous system, Branches of biology, Symptoms and signs, Psychological stress, Pain, Enhancement

The brand has positioned itself as a healthy, effective option for ambitious individuals who aren't just looking for stress relief and pain management.

Key Points: 
  • The brand has positioned itself as a healthy, effective option for ambitious individuals who aren't just looking for stress relief and pain management.
  • Remedy+ has chosen to focus on formulations and methods that lend themselves to personal enhancement.
  • This approach is aptly summarized in in the brand's tag line, "Relax.
  • These products genuinely enhance an individual's ability to perform throughout the day by providing solid nutritional support, mental clarity, and robust levels of stamina.

New Study – WEA Trust Reduces Spend by 56% and Opioid Use by 87% with Kiio Digital Musculoskeletal Care

Retrieved on: 
Thursday, June 24, 2021
Branches of biology, Anatomy, Nervous system, Pain, Human back, Acute pain, Nociception, KIIO-LD, Low back pain, Opioid, Back pain

Overall, Kiio participants had a 56% lower combined medical and pharmacy spend as compared to the traditional care group.

Key Points: 
  • Overall, Kiio participants had a 56% lower combined medical and pharmacy spend as compared to the traditional care group.
  • Kiio members had 47% lower antidepressant use than WEA Trust members with a low back pain diagnosis who did not participate in Kiio.
  • Bartholow continued, WEA Trust believes in taking a leadership role to high-value, innovative care delivery models like Kiio that provide members with immediate access, convenience, and supported control over their health outcomes.
  • Claims-based studies show that Kiio significantly reduces pain, opioid use, and medical spend while improving function, productivity, and quality of life.

Global Pain Management Drugs Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 23, 2021
Health, Pharmaceutical, Nervous system, Branches of biology, Acute pain, Symptoms and signs, Pain, Palliative care, Nociception

The "Pain Management Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pain Management Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global pain management drugs market reached a value of US$ 74 Billion in 2020.
  • Looking forward, the publisher expects the global pain management drugs market to exhibit moderate growth during the forecast period (2021-2026).
  • Pain management drugs perform pharmacological actions on pain receptors and work against discomfort-causing symptoms.

Imbria Pharmaceuticals Announces Enrolment of the First 10 Patients in IMPROVE-DiCE, an Exploratory Phase 2 Study Investigating the impact of IMB-1018972 on Cardiac Energetics, Metabolism and Function in Patients with Type 2 Diabetes

Retrieved on: 
Tuesday, June 22, 2021
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Diabetes, Cardiomyopathy, Acute pain, Angina, Myopathy, Diabetic cardiomyopathy, Organ systems, Medical specialties, IMB-101, Imbria Pharmaceuticals, IMB-101, IMBRIA PHARMACEUTICALS

IMB-101 is a novel, investigational cardiac mitotrope in development for the treatment of cardiovascular disease.

Key Points: 
  • IMB-101 is a novel, investigational cardiac mitotrope in development for the treatment of cardiovascular disease.
  • IMB-101 is currently being investigated in three Phase 2 proof-of-concept studies in patients with hypertrophic cardiomyopathy, stable angina, and type 2 diabetes at risk for diabetic cardiomyopathy.
  • Imbria Pharmaceuticals uses a deep understanding of energy metabolism to develop novel therapies designed to substantially improve the lives of patients with life-altering diseases.
  • Our pipeline also includes IMB-203, designed to address the energy deficiency in patients with rare inborn errors of mitochondrial metabolism.

Cleerly Launches with $43 Million Series B to Provide a New Standard of Care for the Leading Cause of Death – Heart Disease

Retrieved on: 
Monday, June 21, 2021
Health, Medical devices, Technology, Surgery, Software, General Health, Cardiology, Circulatory system, Cardiovascular system, Aging-associated diseases, Medical specialties, Heart diseases, Acute pain, Coronary artery disease, Heart, Myocardial infarction, Cardiovascular disease, Angina, University of Ottawa Heart Institute

Cleerly , the company creating a new standard of care for heart disease, launched today with $43 million in Series B funding and unveiled its first-of-its-kind digital care pathway solution for heart attack prevention.

Key Points: 
  • Cleerly , the company creating a new standard of care for heart disease, launched today with $43 million in Series B funding and unveiled its first-of-its-kind digital care pathway solution for heart attack prevention.
  • Cleerly was founded in 2017 to translate this advanced imaging science into the companys pioneering approach for identifying people at risk of heart attacks.
  • Further, the first symptom of heart disease in more than 50% of individuals diagnosed with coronary artery disease is a heart attack or death.
  • Cleerly is the company creating a new standard of care for heart disease.

Implantable Brain Device Relieves Pain in Early Study

Retrieved on: 
Monday, June 21, 2021
Branches of biology, Pain, Medicine, Pain management, Nociception, Neurotechnology, Acute pain, Electrotherapy, Implant, Transcutaneous electrical nerve stimulation, Chronic pain, Brain implant

NEW YORK, June 21, 2021 /PRNewswire/ -- A computerized brain implant effectively relieves short-term and chronic pain in rodents, a new study finds.

Key Points: 
  • NEW YORK, June 21, 2021 /PRNewswire/ -- A computerized brain implant effectively relieves short-term and chronic pain in rodents, a new study finds.
  • According to the study authors, this suggests that the device reduced the intensity of the pain the rodents experienced.
  • Researchers say the investigation is the first to use a computerized brain implant to detect and relieve bursts of pain in real time.
  • A computer linked to the device then automatically identifies electrical patterns in the brain closely linked to pain.

New Feature in Wound Care Software Fills Patients' Shopping Carts with Physician-Recommended Nutrition

Retrieved on: 
Monday, June 21, 2021
Branches of biology, Clinical medicine, Medicine, Healing, Acute pain, First aid, Injuries, Wound

THE WOODLANDS, Texas, June 21, 2021 /PRNewswire/ --Wound care physicians often struggle to ensure patients receive the proper nutrition to accelerate wound healing.

Key Points: 
  • THE WOODLANDS, Texas, June 21, 2021 /PRNewswire/ --Wound care physicians often struggle to ensure patients receive the proper nutrition to accelerate wound healing.
  • Intellicure already automated the prescribing and ordering of medications and durable medical equipment inside its wound care EHR and its recently released SMART wound care app .
  • Intellicure's latest innovation includes a feature inside its popular wound care EHR and wound care app that empowers physicians towith a single clickfill a patient's online shopping cart with recommended nutritional supplements that help patients achieve successful wound healing.
  • "This capability will help physicians provide wound care patients with the nutrition and education they need to optimize healing and clinical outcomes.

DGAP-News: Antibacterial silver coating technology: aap's silver coated implant used for first time in patient

Retrieved on: 
Friday, June 18, 2021
Musculoskeletal system, Medical Subject Headings, Medical classification, Bone fractures, Prosthetics, Acute pain, Bone fracture, Ankle fracture, Ankle, Implant, Fibula

In the surgery the silver coated LOQTEQ(R) Distal Tibial/Fibula Plate System 3.5 for the treatment of ankle fractures was used.

Key Points: 
  • In the surgery the silver coated LOQTEQ(R) Distal Tibial/Fibula Plate System 3.5 for the treatment of ankle fractures was used.
  • "Three weeks after the first use of a silver coated implant from aap, the healing process looks very encouraging regarding the skin and wound conditions.
  • "Silver is excellently suited for coating medical implants because it has a very broad spectrum of activity and, unlike antibiotics, there is currently no relevant resistance to silver.
  • In addition, aap Implantate AG has an innovation pipeline with promising development projects such as the antibacterial silver coating technology and magnesium-based implants.

NeuraLace Announces FDA 510(k) Clearance and U.S. Launch of Axon Therapy® Peripheral Nerve Stimulation System For Chronic Pain Relief

Retrieved on: 
Thursday, June 17, 2021
Branches of biology, Nervous system, Pain, Nociception, Acute pain, Palliative care, Chronic pain, Pain management, Neuropathic pain, Nerve, Transcutaneous electrical nerve stimulation, Peripheral neuropathy

SAN DIEGO, June 17, 2021 /PRNewswire/ --NeuraLace Medical, Inc., a medical device company focused on improving pain relief among patients suffering from debilitating chronic pain, announced today that it has received FDA 510(k) clearance for Axon Therapy to non-invasively stimulate peripheral nerves and provide chronic nerve pain relief.

Key Points: 
  • SAN DIEGO, June 17, 2021 /PRNewswire/ --NeuraLace Medical, Inc., a medical device company focused on improving pain relief among patients suffering from debilitating chronic pain, announced today that it has received FDA 510(k) clearance for Axon Therapy to non-invasively stimulate peripheral nerves and provide chronic nerve pain relief.
  • "We believe Axon Therapy is a significant step forward on the care continuum that is accessible to patients today and we look forward to bringing sustainable pain relief to patients by launching Axon Therapy in the United States."
  • Axon Therapy delivers focused magnetic pulses which activate the damaged peripheral nerve axons that are required to provide relief from chronic nerve pain.
  • Our mission to end chronic pain inspired us to develop Axon Therapy, with the goal of being the first non-invasive, non-addictive way to effectively treat chronic nerve pain.